Semaglutide clinical trials
Every study registered on ClinicalTrials.gov that lists Semaglutide as an intervention, as of the data edition — what is being tested, in whom, by whom, and how far it has got.
- Registered studies
- 785
- Active or recruiting
- 366
- Completed
- 351
- With posted results
- 109
- Planned or actual enrollment
- 28,394,833participants, summed
| Phase | Studies | Breakdown |
|---|---|---|
| Early phase 1 | 8 | 0 completed, 7 active or recruiting, 0 stopped, 1 other |
| Phase 1 | 116 | 88 completed, 23 active or recruiting, 3 stopped, 2 other |
| Phase 2 | 136 | 52 completed, 72 active or recruiting, 5 stopped, 7 other |
| Phase 3 | 184 | 96 completed, 75 active or recruiting, 7 stopped, 6 other |
| Phase 4 | 121 | 28 completed, 74 active or recruiting, 5 stopped, 14 other |
| Not applicable | 77 | 17 completed, 51 active or recruiting, 0 stopped, 9 other |
| Observational | 143 | 70 completed, 64 active or recruiting, 5 stopped, 4 other |
Conditions studied
- Obesity195
- Diabetes Mellitus, Type 2173
- Diabetes71
- Type 2 Diabetes68
- Overweight56
- Obesity & Overweight31
- Healthy28
- Weight Loss17
- Type 2 Diabetes Mellitus (T2DM)13
- Diabetes Mellitus11
- Healthy Volunteers10
- Type 2 Diabetes Mellitus10
Lead sponsors
- Novo Nordisk A/S262
- Brigham and Women's Hospital19
- University of Colorado, Denver10
- Eli Lilly and Company10
- Vanderbilt University Medical Center6
- Mayo Clinic6
- Yale University6
- The Cleveland Clinic6
The registry, study by study
Showing the 160 most relevant of 785 studies (active first, then newest start date). Registration is not evidence of benefit; many registered studies never publish. Status and dates are as reported by sponsors to ClinicalTrials.gov.
| Study | Phase | Status | Start | n | Sponsor |
|---|---|---|---|---|---|
| NCT07586150Personalized Pharmaco-Lifestyle Interventions for Severe Mental Illnesses (LIFETRAIN) | N/A | Not yet recruiting | Oct 2028 | 140 | Ludwig-Maximilians - University of Munich |
| NCT07430332GLP-1 RA for Stage 1 Type 1 Diabetes | Phase 2 | Not yet recruiting | Sep 2027 | 15 | Children's Hospital Medical Center, Cincinnati |
| NCT07797036Postpartum Semaglutide to Reduce Cardiometabolic Risk After Gestational Diabetes Mellitus | Phase 2/Phase 3 | Not yet recruiting | Sep 2027 | 226 | University of Massachusetts, Worcester |
| NCT07711548Can Two Dietary Interventions Maintain Weight Loss for 12 Months After GLP-1 Therapy in Adults With Overweight/Obesity? | N/A | Not yet recruiting | Mar 2027 | 292 | Knut Mai |
| NCT07754045Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults | Phase 2 | Not yet recruiting | Feb 2027 | 202 | Lumos Pharma |
| NCT07731256Semaglutide for Low Back Pain | Phase 2 | Not yet recruiting | Feb 2027 | 250 | Washington University School of Medicine |
| NCT05714683Regulatory Post Marketing Surveillance (rPMS) Study of Rybelsus (Oral Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea | Observational | Not yet recruiting | Jan 2027 | 600 | Novo Nordisk A/S |
| NCT07787936GLP-1/GIP Receptor Agonists in Obesity-Related HFpEF: The GLIDE-HF Registry | Observational | Not yet recruiting | Jan 2027 | 150 | Miedziowe Centrum Zdrowia SA |
| NCT07820358Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer | Phase 2 | Not yet recruiting | Jan 2027 | 48 | The Methodist Hospital Research Institute |
| NCT07858331Patient-centred Intervention With Virtual Support for Obesity and Kidney Transplant Access | Phase 4 | Not yet recruiting | Jan 2027 | 880 | Kristin Clemens |
| NCT07614412SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes. | Phase 2 | Not yet recruiting | Jan 2027 | 240 | Ministry of Health, Saudi Arabia |
| NCT07462663SHAPE-ENDO: Pilot Randomized Trial of Multimodal Pre-Surgical Optimization Versus Standard Surgery in Patients With Obesity and Early-Stage Endometrial Cancer | Phase 4 | Not yet recruiting | Jan 2027 | 80 | Hospital Universitari de Bellvitge |
| NCT07770282Efficacy and Safety of Semaglutide Versus Placebo on Cardiometabolic Profile in Patients With Schizophrenia With Metabolic Syndrome | Phase 3 | Not yet recruiting | Dec 2026 | 600 | All India Institute of Medical Sciences, Bhubaneswar |
| NCT07760948HMB Plus Vitamin D to Preserve Muscle in Older Adults Starting Semaglutide | Phase 2 | Not yet recruiting | Dec 2026 | 90 | Vanderbilt University Medical Center |
| NCT07855900SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight | Phase 3 | Not yet recruiting | Nov 2026 | 350 | Boehringer Ingelheim |
| NCT07866066Maridebart Cafraglutide Versus Semaglutide in Participants With Type 2 Diabetes | Phase 3 | Not yet recruiting | Nov 2026 | 1,300 | Amgen |
| NCT06546384GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease | N/A | Not yet recruiting | Nov 2026 | 64 | Insel Gruppe AG, University Hospital Bern |
| NCT07832084Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s | Phase 4 | Not yet recruiting | Nov 2026 | 60 | Jing Luo |
| NCT07027969Metabolic Surgery for Atrial Fibrillation Elimination | Phase 4 | Not yet recruiting | Nov 2026 | 100 | Ali Aminian |
| NCT07878494Dietary, Medication, and Endoscopic Interventions for Post-Bariatric Hypoglycemia | N/A | Not yet recruiting | Nov 2026 | 30 | Stanford University |
| NCT07249554Combination Therapy for Alcohol Use Disorder | Phase 2 | Not yet recruiting | Nov 2026 | 45 | Johns Hopkins University |
| NCT07845994SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years | Phase 3 | Not yet recruiting | Nov 2026 | 50 | University Hospital, Angers |
| NCT07511543Glucagon-like Peptide-1 Receptor Agonists for Endovascular Stroke Thrombectomy | Phase 2 | Not yet recruiting | Oct 2026 | 100 | Population Health Research Institute |
| NCT07840729Evaluate the Safety and Tolerability of Multiple Doses of JMT206 Injection in Obese Participants | Phase 1 | Not yet recruiting | Oct 2026 | 90 | Shanghai JMT-Bio Inc. |
| NCT06977438GLP-1 Plus Lifestyle for Overall Wellness: Find Your Way Forward | Phase 4 | Not yet recruiting | Oct 2026 | 1,020 | University of Minnesota |
| NCT07874971Short Term Effects of Semaglutide on Body Composition and Performance | N/A | Not yet recruiting | Oct 2026 | 41 | Morten Hostrup, PhD |
| NCT07874932Long-Term Effects of Semaglutide on Body Composition and Performance in Running | N/A | Not yet recruiting | Oct 2026 | 41 | Morten Hostrup, PhD |
| NCT07812597A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ) | Phase 2 | Not yet recruiting | Oct 2026 | 210 | Beijing QL Biopharmaceutical Co.,Ltd |
| NCT07627191GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer | Early Ph 1 | Recruiting | Oct 2026 | 30 | University of Arizona |
| NCT07855133A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication | Phase 1 | Recruiting | Oct 2026 | 60 | Novo Nordisk A/S |
| NCT07423481Weight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity | Observational | Not yet recruiting | Oct 2026 | 3,000 | Nantes University Hospital |
| NCT07816744Danish Trial of Weight Loss to Reduce Atrial Fibrillation Progression | N/A | Not yet recruiting | Oct 2026 | 480 | Axel Brandes |
| NCT07820722Assessing Heart and Brain Metabolism in Type II Diabetes Mellitus Patients Using Carbon-13 MRI | Early Ph 1 | Not yet recruiting | Oct 2026 | 32 | Sunnybrook Health Sciences Centre |
| NCT07872904FutureShape Family | Phase 4 | Not yet recruiting | Oct 2026 | 400 | Signe Torekov |
| NCT07772960Semaglutide Dose Effects on Metabolic and Stress Hormone, Craving and Alcohol Use Outcomes | Phase 1 | Not yet recruiting | Oct 2026 | 90 | Yale University |
| NCT07737522Myocardial Metabolic Flux in Pulmonary Arterial Hypertension | Phase 2 | Not yet recruiting | Oct 2026 | 32 | Imperial College London |
| NCT07755085GLP-1s in Hip and Knee Arthroplasty | Phase 4 | Not yet recruiting | Oct 2026 | 100 | Nova Scotia Health Authority |
| NCT07859150Semaglutide 2.4 mg Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE) | Phase 4 | Not yet recruiting | Oct 2026 | 104 | General Committee of Teaching Hospitals and Institutes, Egypt |
| NCT07859137Semaglutide Before Primary Metabolic and Bariatric Surgery in Patients With BMI 60 kg/m² or Higher | Phase 4 | Not yet recruiting | Oct 2026 | 100 | General Committee of Teaching Hospitals and Institutes, Egypt |
| NCT07859176Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic and Bariatric Surgery | Phase 4 | Not yet recruiting | Oct 2026 | 100 | General Committee of Teaching Hospitals and Institutes, Egypt |
| NCT07859189Immediate Versus Criterion-triggered Semaglutide for Suboptimal Clinical Response One Year After Primary Metabolic and Bariatric Surgery | Phase 4 | Not yet recruiting | Oct 2026 | 100 | General Committee of Teaching Hospitals and Institutes, Egypt |
| NCT07389941Semaglutide PrIor to CathEeter Ablation in Patients With Atrial Fibrillation | Phase 4 | Not yet recruiting | Oct 2026 | 240 | University of Luebeck |
| NCT07859163Semaglutide Given Before and After Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass for Recurrent Weight Gain | Phase 4 | Not yet recruiting | Oct 2026 | 100 | General Committee of Teaching Hospitals and Institutes, Egypt |
| NCT07845500A Study to Learn About Switching to a Monthly Study Medicine Called Berobenatide (PF-08653944) to Help Keep Weight Off in People With Overweight or Obesity | Phase 3 | Recruiting | Sep 2026 | 660 | Pfizer |
| NCT07845578A Research Study Looking Into How a High Dose of s.c. Semaglutide Works With Emptying of the Stomach in People With Excess Body Weight | Phase 1 | Not yet recruiting | Sep 2026 | 60 | Novo Nordisk A/S |
| NCT07668414A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide | Phase 3 | Recruiting | Sep 2026 | 650 | Novo Nordisk A/S |
| NCT07846956NAION in Non-Diabetic Obese Patients Using GLP-1 Receptor Agonists: A Real-World Study | Observational | Not yet recruiting | Sep 2026 | 28 | Istanbul Saglik Bilimleri University |
| NCT07743983A Study of BGM0504 in Early T2DM With Obesity | Phase 3 | Recruiting | Sep 2026 | 372 | BrightGene Bio-Medical Technology Co., Ltd. |
| NCT06073184Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium | Phase 2 | Recruiting | Sep 2026 | 71 | GynOncTrials |
| NCT07817251Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema | Phase 3 | Recruiting | Sep 2026 | 210 | Novo Nordisk A/S |
| NCT07713992Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide | N/A | Not yet recruiting | Sep 2026 | 72 | Tianjin Medical University |
| NCT07653477Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2) | Phase 3 | Recruiting | Sep 2026 | 956 | The United Bio-Technology (Hengqin) Co., Ltd. |
| NCT06913023Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus | Phase 2/Phase 3 | Not yet recruiting | Sep 2026 | 37 | University Health Network, Toronto |
| NCT07769047Semaglutide and Structured Lifestyle Support to Improve Heart and Blood Vessel Health in Postmenopausal Obese Breast Cancer Survivors Taking Aromatase Inhibitors | Phase 4 | Not yet recruiting | Sep 2026 | 50 | Mayo Clinic |
| NCT07642635Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy | Phase 1/Phase 2 | Not yet recruiting | Sep 2026 | 30 | Vanderbilt University Medical Center |
| NCT07485062Exercise and Diabetes Interventions to Improve Brain Health in Older Adults With Type 2 Diabetes | Phase 4 | Not yet recruiting | Sep 2026 | 164 | Western University, Canada |
| NCT06934655Early Reinitiation of Semaglutide Post-Sleeve Gastrectomy in Youth | Phase 3 | Recruiting | Sep 2026 | 150 | Children's Hospital Los Angeles |
| NCT07728812Pragmatic Trial to Study the Cost-Effectiveness of MyPhenome-RX Test to Guide Anti-Obesity Pharmacotherapy | N/A | Not yet recruiting | Sep 2026 | 424 | Phenomix Sciences |
| NCT07651319Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease | Phase 1/Phase 2 | Recruiting | Sep 2026 | 30 | The Methodist Hospital Research Institute |
| NCT07770152Semaglutide in Youth With Autism Spectrum Disorder | Phase 4 | Not yet recruiting | Sep 2026 | 42 | Children's Hospital Medical Center, Cincinnati |
| NCT07783854A Randomized Controlled Study of Dose-tapering Regimen of Semaglutide for Weight-Loss Maintenance in Adults With Overweight or Obesity | Phase 4 | Not yet recruiting | Sep 2026 | 72 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology |
| NCT07677995Free Fatty Acid Effects In Type 2 Diabetes | N/A | Enrolling by invitation | Sep 2026 | 60 | University of Ulster |
| NCT07849348Study on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-Diabetic Adult Patients With Obesity Complicated by Chronic Kidney Disease With Albuminuria | N/A | Not yet recruiting | Sep 2026 | 266 | Peking University People's Hospital |
| NCT07617155GLP-1 Agonists for Prevention of Recurrent Hypertriglyceridemic Acute Pancreatitis | Phase 4 | Not yet recruiting | Sep 2026 | 396 | Peking Union Medical College Hospital |
| NCT07622810BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity | Phase 3 | Not yet recruiting | Sep 2026 | 352 | Carnot Laboratories |
| NCT07628985BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes | Phase 3 | Not yet recruiting | Sep 2026 | 374 | Carnot Laboratories |
| NCT07509112Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study | Phase 2 | Not yet recruiting | Sep 2026 | 40 | Kirby Institute |
| NCT07478653MODERN-Dental: Pediatric Obesity, Cardiometabolic Risks, And Periodontal Disease | N/A | Recruiting | Aug 2026 | 50 | Oelisoa Andriankaja |
| NCT07870538A Neuropsychobiological Approach to Optimize Patient Selection for GLP-1-based Pharmacotherapy for Weight Management Across the Binge Eating Spectrum | Phase 4 | Recruiting | Aug 2026 | 96 | Universitaire Ziekenhuizen KU Leuven |
| NCT07781371A Retrospective Real-World Cohort Study | Observational | Active, not recruiting | Aug 2026 | 100,000 | Novo Nordisk A/S |
| NCT07720466Salivary Function and Dental Changes During GLP-1 Therapy | Observational | Not yet recruiting | Aug 2026 | 40 | Bilecik Seyh Edebali Universitesi |
| NCT07770841Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight | Phase 3 | Recruiting | Aug 2026 | 450 | Novo Nordisk A/S |
| NCT07767175A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or Obesity | Phase 1 | Recruiting | Aug 2026 | 142 | Novo Nordisk A/S |
| NCT07563699Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes Mellitus | Phase 1/Phase 2 | Recruiting | Aug 2026 | 24 | Mapi Pharma Ltd. |
| NCT07760532Comparing Facial Aging Between Identical Twins With 3D Imaging | Observational | Not yet recruiting | Aug 2026 | 200 | Ponsky Facial Aesthetics And Plastic Surgery, Llc |
| NCT07213323Probiotic Intervention for Digestive Health in Obese Patients Initiating GLP-RA Treatment | N/A | Recruiting | Aug 2026 | 50 | Hospices Civils de Lyon |
| NCT07745504A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight | Phase 3 | Recruiting | Aug 2026 | 285 | Novo Nordisk A/S |
| NCT07282613A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes | Phase 3 | Recruiting | Aug 2026 | 80 | Novo Nordisk A/S |
| NCT07592546Translational Health Research Into Vascular and Neurocognitive Effects of Weight Loss | Phase 4 | Not yet recruiting | Aug 2026 | 240 | Alain Dagher |
| NCT07668765GLP-1 Receptor Agonists and Early Proctologic Effects in Morbid Obesity | Observational | Not yet recruiting | Aug 2026 | 100 | Gazi University |
| NCT07695454Imaging in Semaglutide Study | Observational | Recruiting | Jul 2026 | 10 | The Cleveland Clinic |
| NCT07218354Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized Controlled Trial for Alcohol Use Disorder (CRAVE) | Phase 3 | Recruiting | Jul 2026 | 622 | VA Office of Research and Development |
| NCT07728669Digital Dietary Intervention for Patients Receiving GLP-1 Receptor Agonist Therapy | N/A | Recruiting | Jul 2026 | 120 | Kazakh Academy of Nutrition |
| NCT07732426Effects of Semaglutide on Brain Dopamine Responses to Food Cues in Adults With Obesity and Food Addiction Tendencies | N/A | Recruiting | Jul 2026 | 30 | Seoul National University Hospital |
| NCT07662213A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus | Phase 3 | Recruiting | Jul 2026 | 1,200 | AstraZeneca |
| NCT07411378Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss. | Phase 2 | Not yet recruiting | Jul 2026 | 164 | Biophytis |
| NCT07720414Effects of GLP-1 RAs on Human Lactation Outcomes | Observational | Recruiting | Jul 2026 | 18 | University of Colorado, Denver |
| NCT07430059Safety, Tolerability and Pharmacokinetics of a Subcutaneous Semaglutide Implant | Phase 1 | Not yet recruiting | Jul 2026 | 20 | Vivani Medical, Inc |
| NCT07727473Preoperative Semaglutide Prior to Radical Prostatectomy | Early Ph 1 | Not yet recruiting | Jul 2026 | 20 | Banner Health |
| NCT07801820Phase 2 Clinical Study of MWN109 Tablets in Participants With Type 2 Diabetes Mellitus | Phase 2 | Recruiting | Jun 2026 | 240 | Shanghai Minwei Biotechnology Co., Ltd |
| NCT07668388A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes | Phase 2 | Recruiting | Jun 2026 | 300 | Novo Nordisk A/S |
| NCT07724340A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity | Phase 2 | Active, not recruiting | Jun 2026 | 150 | Antag Therapeutics |
| NCT07728383A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity | Phase 4 | Recruiting | Jun 2026 | 40 | Gila Therapeutics, Inc. |
| NCT07021937Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity | Phase 3 | Not yet recruiting | Jun 2026 | 120 | University of Colorado, Denver |
| NCT07613437GLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized Trial | Phase 2 | Not yet recruiting | Jun 2026 | 200 | Chinese University of Hong Kong |
| NCT07673900Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants | Phase 1 | Recruiting | Jun 2026 | 62 | Terrestrial Bio, Inc. |
| NCT07702461Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists | Observational | Recruiting | Jun 2026 | 300 | Ohio State University |
| NCT07639021A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity | Phase 2 | Active, not recruiting | Jun 2026 | 233 | Novo Nordisk A/S |
| NCT07444073Assessing Biological Aging in a Real-World Medical Weight Loss Program Using the LinAge2 Clinical Clock | Observational | Not yet recruiting | Jun 2026 | 440 | National University of Singapore |
| NCT07570810Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM | N/A | Not yet recruiting | Jun 2026 | 30 | Shanghai Jiao Tong University School of Medicine |
| NCT07282769Semaglutide (Wegovy) Treatment for Trichotillomania | Phase 2 | Not yet recruiting | Jun 2026 | 10 | University of Chicago |
| NCT07621640Brown Adipose Tissue as a Mechanistic Determinant of Semaglutide Treatment Response in Obesity (BAT-Sema Study) | N/A | Not yet recruiting | Jun 2026 | 80 | Hallym University |
| NCT07858864GLP-1 Receptor Agonist Use and Sarcopenia in Obese Individuals Without Diabetes | Observational | Recruiting | May 2026 | 42 | Istanbul Saglik Bilimleri University |
| NCT07564414A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight | Phase 3 | Recruiting | May 2026 | 2,500 | Novo Nordisk A/S |
| NCT07400107AMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight | Phase 3 | Not yet recruiting | May 2026 | 1,000 | Novo Nordisk A/S |
| NCT07597018A Research Study to Compare Blood Levels of Cagrilintide After Multiple Doses of Different Versions of Cagrilintide in Adults With Overweight or Obesity | Phase 1 | Recruiting | May 2026 | 234 | Novo Nordisk A/S |
| NCT07272837Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass | Observational | Recruiting | May 2026 | 50 | University of Alberta |
| NCT07428746Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes | Phase 3 | Recruiting | May 2026 | 20 | Emory University |
| NCT07539415A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers | Phase 1 | Recruiting | May 2026 | 72 | Daewoong Pharmaceutical Co. LTD. |
| NCT07487103Efficacy and Safety of QLG1091 vs Rybelsus as add-on to Metformin in Subjects With Type 2 Diabetes | Phase 3 | Not yet recruiting | May 2026 | 478 | Qilu Pharmaceutical Co., Ltd. |
| NCT07633639GLP-1 Therapy After Bariatric Surgery in Chinese Patients With Obesity | N/A | Recruiting | May 2026 | 200 | China-Japan Friendship Hospital |
| NCT07179120Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health | Phase 2 | Not yet recruiting | May 2026 | 180 | First Affiliated Hospital of Wenzhou Medical University |
| NCT07588984GLP-1 Medication & Behavioral Health Programs on Weight & Metabolic Outcomes: FLOURISH and THRIVE Prospective Cohort Study | Observational | Not yet recruiting | Apr 2026 | 2,310 | Noom Inc. |
| NCT07599046Fecal Microbiota Transplantation (FMT) Combined With Calorie-Restricted Diet and Semaglutide in Patients With Obesity and Type 2 Diabetes | N/A | Not yet recruiting | Apr 2026 | 20 | Eighth Affiliated Hospital, Sun Yat-sen University |
| NCT07502508Phase 2 Trial of Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Achieving Glycemic Targets While Using GLP-1-Based Therapy | Phase 2 | Recruiting | Apr 2026 | 60 | Biomea Fusion Inc. |
| NCT07523633Effect of Semaglutide on Cannabis Use in Adults With Cannabis Use Disorder | Phase 2 | Recruiting | Apr 2026 | 100 | Anders Fink-Jensen, MD, DMSci |
| NCT07581145Effect of Semaglutide on Healing of Foot Ulcers in Type 2 Diabetes Patients | Phase 3 | Recruiting | Apr 2026 | 52 | Ole Lander Svendsen |
| NCT07653412Precision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists. | Observational | Recruiting | Apr 2026 | 220 | National and Kapodistrian University of Athens |
| NCT07221214GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV | Phase 2 | Recruiting | Apr 2026 | 200 | Vanderbilt University Medical Center |
| NCT07415954A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes | Phase 2 | Recruiting | Apr 2026 | 270 | Novo Nordisk A/S |
| NCT07527195Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health) | Phase 1 | Recruiting | Apr 2026 | 100 | Novo Nordisk A/S |
| NCT07547878Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) | Phase 4 | Enrolling by invitation | Apr 2026 | 64 | Baylor Research Institute |
| NCT07107334A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia | Phase 2 | Recruiting | Apr 2026 | 20 | University of Florida |
| NCT07554417Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1 | Phase 4 | Not yet recruiting | Apr 2026 | 20 | William Marsh Rice University |
| NCT07466017A Study of CS060380 Tablets in Patients With MASH and Obesity | Phase 2 | Active, not recruiting | Apr 2026 | 130 | Cascade Pharmaceuticals, Inc |
| NCT07558863Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 Diabetes | Phase 4 | Recruiting | Apr 2026 | 60 | The First Affiliated Hospital with Nanjing Medical University |
| NCT07090343Semaglutide in Patients Undergoing Transcatether Aortic Valve Replacement | Phase 3 | Not yet recruiting | Apr 2026 | 826 | Leiden University Medical Center |
| NCT07589322Comparative Observation of Metabolic and Pharmacologic Adipose Remodeling With Enhanced Incretin AgonisTs | N/A | Recruiting | Mar 2026 | 120 | Tri-Service General Hospital (TSGH) |
| NCT07446439A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use | Phase 3 | Recruiting | Mar 2026 | 280 | Vanda Pharmaceuticals |
| NCT07223983Semaglutide (SEMA) for Alcohol Use Disorder (AUD) After Metabolic and Bariatric Surgery (MBS) | Phase 1 | Active, not recruiting | Mar 2026 | 4 | Yale University |
| NCT07446998Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss | Phase 2 | Active, not recruiting | Mar 2026 | 239 | Veru Inc. |
| NCT07275697Waiting on Atrial Fibrillation Intervention Therapy (WAIT) Study | Phase 4 | Recruiting | Mar 2026 | 200 | Emma Svennberg |
| NCT07505303MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial | Phase 2 | Active, not recruiting | Mar 2026 | 151 | Eccogene |
| NCT07317115Side-to-Side Duodeno-ileostomy Versus Semaglutide in Adults With Obesity and Type 2 Diabetes | N/A | Recruiting | Mar 2026 | 20 | GT Metabolic Solutions, Inc. |
| NCT07361874IMPACT-MACS: Adrenalectomy vs Semaglutide for Metabolic Outcomes in Mild Autonomous Cortisol Secretion | N/A | Recruiting | Mar 2026 | 75 | University of Texas Southwestern Medical Center |
| NCT07465965A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults | Phase 1 | Recruiting | Mar 2026 | 60 | Shanghai World Leader Pharmaceutical Co., Ltd. |
| NCT06975111Focusing on the Menopausal Transition to Improve Mid-Life Women's Health | Phase 2/Phase 3 | Recruiting | Mar 2026 | 200 | University of Colorado, Denver |
| NCT07605572Impact of GLP-1 Receptor Agonists on Dry Eye Disease in Patients With Type 2 Diabetes Mellitus and Obesity | Observational | Recruiting | Mar 2026 | 100 | Attikon Hospital |
| NCT07483801DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot Studies | Phase 4 | Not yet recruiting | Mar 2026 | 112 | Cambridge University Hospitals NHS Foundation Trust |
| NCT07204249Glutide for Ending Methamphetamine | Phase 2 | Recruiting | Feb 2026 | 162 | San Francisco Department of Public Health |
| NCT07187830Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKD | Observational | Recruiting | Feb 2026 | 52 | University of Alberta |
| NCT07456774A Two-armed Real-world Study of Ozempic (OW Semaglutide) to Evaluate Its Adherence and Persistence Compared With Other Anti-diabetic Drugs Among Adult T2DM Patients in China | Observational | Enrolling by invitation | Feb 2026 | 100,000 | Novo Nordisk A/S |
| NCT07059377Semaglutide for Smoking Cessation in Patients With Diabetes | Phase 3 | Recruiting | Feb 2026 | 100 | Ottawa Heart Institute Research Corporation |
| NCT06836284The Evira Study: Additional Support During Obesity Treatment | N/A | Recruiting | Feb 2026 | 40 | Karolinska Institutet |
| NCT07325500Incretin Microdosing for Cardiometabolic Health in People With HIV | Phase 2 | Recruiting | Feb 2026 | 30 | The University of Texas Health Science Center, Houston |
| NCT07195994A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes | N/A | Recruiting | Feb 2026 | 90 | QuickSilver Scientific |
| NCT05689372Regulatory Post Marketing Surveillance (rPMS) Study of Ozempic (Semaglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea | Observational | Enrolling by invitation | Feb 2026 | 600 | Novo Nordisk A/S |
| NCT07323134The Effect of Semaglutide on the Intestinal Flora in Obesity | Observational | Not yet recruiting | Feb 2026 | 40 | Beijing Chao Yang Hospital |
| NCT07294950Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination | Phase 3 | Recruiting | Feb 2026 | 98 | Mount Sinai Hospital, Canada |
| NCT07391267Pathogenesis of Chronic Kidney Disease Associated With Metabolic Dysfunction- Associated Fatty Liver Disease (MAFLD) and Treatment Response of Oral Semaglutide. | N/A | Not yet recruiting | Feb 2026 | 90 | Institute of Liver and Biliary Sciences, India |
| NCT07392151Reversal to Normoglycemia by Treating Prediabetes | Phase 3 | Not yet recruiting | Feb 2026 | 158 | Michael Mæng |
| NCT07382388A Real-World Study on the Impact of Weight Loss on Treatment Efficacy in Overweight/Obese Patients With Plaque Psoriasis | Observational | Not yet recruiting | Jan 2026 | 70 | Peking University Third Hospital |
| NCT07779343OBESIAL: A Prospective Interventional Real-world Study of a Multidisciplinary Obesity Management Programme | N/A | Recruiting | Jan 2026 | 300 | University of Health Sciences, Algeria |
| NCT07213466Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder | Phase 4 | Recruiting | Jan 2026 | 100 | Mayo Clinic |
| NCT07242534Effect of Semaglutide on Embryo Quality in Overweight and Obese Patients Undergoing In Vitro Fertilization. | Phase 4 | Recruiting | Jan 2026 | 62 | Fundacion Dexeus |
| NCT07040592Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide | Phase 2 | Recruiting | Jan 2026 | 30 | Yale University |
| NCT07401992Effects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis | Phase 4 | Recruiting | Jan 2026 | 62 | Hospital Universitario Dr. Jose E. Gonzalez |
| NCT07227948Repurposing Semaglutide for the Treatment of Cocaine Use Disorder | Phase 2 | Recruiting | Jan 2026 | 75 | The University of Texas Health Science Center, Houston |
| NCT07253285A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight | Phase 3 | Recruiting | Jan 2026 | 460 | Novo Nordisk A/S |
| NCT07640139Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes | Observational | Enrolling by invitation | Jan 2026 | 125,000 | Indiana University |
Run this search on ClinicalTrials.gov → Query term: semaglutide